Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference

Core Viewpoint - Fulcrum Therapeutics, Inc. is actively engaging with investors through a fireside chat at the Stifel Healthcare Conference, highlighting its focus on developing treatments for genetically defined rare diseases [1][2]. Company Overview - Fulcrum Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing small molecules aimed at improving the lives of patients with genetically defined rare diseases, particularly in areas with high unmet medical needs [3]. - The company's lead program is pociredir, a small molecule designed to increase fetal hemoglobin expression, currently in development for treating sickle cell disease (SCD) [3]. - Fulcrum employs proprietary technology to identify drug targets that can modulate gene expression, addressing the root causes of gene misexpression [3].